Article
Polymorphism and expression of macrophage migration inhibitory factor does not contribute to glucocorticoid resistance in idiopathic thrombocytopenic purpura.
Die Pharmazie - 1 Oct 2013
Lao Wansheng, Xiang Yang, Fang Meiyun, Yang Xifei
Abstract excerpt
Glucocorticoids (GCs) are considered the important drugs used in treatment of idiopathic thrombocytopenic purpura (ITP). However, about 10-30% patients with ITP develop GC resistance after standard treatment with GC. The macrophage migration inhibitory factor (MIF) has been shown to act as a counter-regulator of the anti-inflammatory and immunosuppressive effects of GCs on immune cells. In addition, MIF-173G/C...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
